death

A new implantable device has been found to reduce the risk of death from congestive heart failure by 40 percent, triggering the early halt of a national trial of the device. “This trial was the largest one in history to test an implanted pacemaker or defibrillator, and it represents a landmark study for the treatment of congestive heart failure,” says Mitchell N. Faddis, M.D., Ph.D., assistant professor of medicine at Washington University School of Medicine in St. Louis. “I think this is one of the most important therapies developed in the last decade for treatment of severe heart disease.”